Adagrasib is an oral Kirsten Rat Sarcoma Virus (KRAS) inhibitor that received approval by the Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in 2022 and showcases durable clinical benefits in patients.